Patent
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	•	Merck & Co., Inc.						
1 ippitouite	•	more a co., me.						
Int'l Appln. No. :	:	PCT/US2005/009810						
Int'l Date Filed	:	23 March 2005 (23/03/20	05)					
Serial No.	:	(To be assigned)	Case No.: 21573YP					
Filed :		September 22, 2006						
For :		HETEROARYL PIPERII TRANSPORTER INHIBI						
	Commissioner for Patents Alexandria, Virginia 22313-1450							

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

DATE OF DEPOSIT 1-22-2006

EVELOGO 8885 US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS

BEING DEPOSITED WITH THE UNITED STATES POSTAL

SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"

ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO

COMMISSIONER FOR PATENTS, P.O. BOX 1450,

ALEXANDRIA, VIRGINIA 22313-7450.

MAILED BY UNITED CUMBER

DATE

10/593950

Serial No.: Case No.: To be assigned 21573YP

Page 2

2

IAP6 Rec'd PCT/PTO 22 SEP 2006

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.98(a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application are not enclosed herewith. Copies of the other references that are cited on the attached form PTO-1449 are enclosed herewith.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

LABric Thies

∦eg. No. 35,382

Attorney for Applicant

MERCK & CO., Inc.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(732) 594-3904

Date: September 22, 2006

SUBSTITUTE for PTO/SB/08A (07-05), Information Disclosure Statement by Applicant
SUBSTITUTE for PTO/SB/08A (07-05), Information Disclosure Statement by Applicant
SUBSTITUTE for PTO/SB/08A (07-05), Information Disclosure Statement by Office Its DEPARTMENT OF DO NATIONAL OF SUBSTITUTE OF SUBSTITUT

Su	bstitute for form 1449A/PTO		· · · · · · · · · · · · · · · · · · ·	Patent and Trademark Office: U.S DEPARTMENT OF COMMERCE COMPLETE IF KNOWN			
	INFORMATION DISCLOSURE			Application Number	10/593950		
9	TATEMENT RV	A DE	DIICANT	Filing Date	September 22, 2006		
STATEMENT BY APPLICANT			LICANI	First Named Inventor	Blackaby, et al		
	(usa sa manu shaata	~~ ~~		Group Art Unit			
(use as many sheets as necessary)			cessary) 	Examiner Name			
Sheet	1	of	2	Attorney Docket Number	21573YP		

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)		Date of Publication of Cited Document MM-DD-YYYY		
		US 6,664,273		Burneet, et al.	12/16/2003		
		US 2003/0013720		Hobbs, et al.	01/16/2003		
			-				
_							

	FOREIGN PATENT DOCUMENTS						
			Foreign Patent Documen	it		Date of Publication of	
Examiner Initials*	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	
-						· ·	

_							
					76.40. 10.47.47.47		
							
			·				

Examiner Signature Date Considered	
------------------------------------	--

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUBSTITUTE for PTO/SB/08A (07-05), Information Disclosure Statement by Applicant Program and Tradement Office ILLS DEPARTMENT OF SCHOOL OF STATEMENT OF SCHOOL OF STATEMENT OF SCHOOL OF SCHOOL OF STATEMENT OF SCHOOL O

					Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE	
-	bstitute for form 1449B/PTO				COMPLETE IF KNOWN	1
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/593950			
		DI ICANT	Filing Date	September 22, 2006		
3	STATEMENT BY APPLICANT			First Named Inventor	Blackaby, et al	
				Group Art Unit		
	(use as many sheets	as n	ecessary)	Examiner Name		
Sheet	2	of	2	Attorney Docket Number	21573YP	_

7

Examiner Cite Include name of the author, title, date, page(s), volume-issue number(s) and place of publication. Wermuth C.G. The Practice of Medicinal Chemistry, Academic Press, (1996) Chapter 13, pages 211-213 Wermuth C.G. The Practice of Medicinal Chemistry, Academic Press, (1996) Chapter 13, pages 211-213 In a control of the practice of Medicinal Chemistry, Academic Press, (1996) Chapter 13, pages 211-213 In a control of the practice of Medicinal Chemistry, Academic Press, (1996) Chapter 13, pages 211-213 In a control of the practice of Medicinal Chemistry, Academic Press, (1996) Chapter 13, pages 211-213 In a control of the practice of Medicinal Chemistry, Academic Press, (1996) Chapter 13, pages 211-213 In a control of the practice of Medicinal Chemistry, Academic Press, (1996) Chapter 13, pages 211-213 In a control of the practice of Medicinal Chemistry, Academic Press, (1996) Chapter 13, pages 211-213 In a control of the practice of Medicinal Chemistry, Academic Press, (1996) Chapter 13, pages 211-213 In a control of the practice of Medicinal Chemistry, Academic Press, (1996) Chapter 13, pages 211-213 In a control of the practice of Medicinal Chemistry, Academic Press, (1996) Chapter 13, pages 211-213 In a control of the practice of Medicinal Chemistry, Academic Press, (1996) Chapter 13, pages 211-213 In a control of the practice of Medicinal Chemistry, Academic Press, (1996) Chapter 13, pages 211-213 In a control of the practice of Medicinal Chemistry, Academic Press, (1996) Chapter 13, pages 211-213 In a control of the practice of Medicinal Chemistry, Academic Press, (1996) Chapter 13, pages 211-213 In a control of the practice of Medicinal Chemistry, Academic Press, (1996) Chapter 13, pages 211-213 In a control of the practice of th	NON PATENT LITERATURE DOCUMENTS						
Wermuth C.G. The Practice of Medicinal Chemistry, Academic Press, (1996) Chapter 13, pages 211-213	Examiner Initials*		Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.				
			Wermuth C.G. The Practice of Medicinal Chemistry, Academic Press, (1996) Chapter 13, pages 211-213				

Examiner Signature	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.